Compare Novo Nordisk A/S (NVO) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Novo Nordisk A/S trades at $44.91 (market cap $200.69B), while iShares 1 3 Year Treasury Bond ETF trades at $81.65. The key difference: Novo Nordisk A/S pays a 3.98% dividend while iShares 1 3 Year Treasury Bond ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVO | SHY | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | Fixed Income |
52-Week High | $63.98 | $83.18 |
52-Week Low | $35.29 | $81.59 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
SHY is currently trading at $81.66, showing minimal daily movement with a slight decline of 0.04%. The technical picture appears bearish with moving averages signaling caution, though oscillators suggest some buying opportunity. Recent corporate actions include consistent dividend payments scheduled through mid-2026, providing income stability for shareholders amid market volatility.
The outlook for SHY reflects mixed signals with technical indicators showing bearish momentum but potential oversold conditions. Investment opportunities include dividend income stability, while risks center on broader bond market volatility and interest rate sensitivity. The stock faces headwinds from rising Treasury yields and inflation concerns that could pressure fixed-income investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
